ImmunityBio Reports Long-Term ANKTIVA and BCG Data
Journal of Urology publication of Phase 2/3 data reported 84% cystectomy avoidance at three years and complete responses beyond 53 months. Grade 3 adverse events were reported in 4% of patients.
Journal of Urology publication of Phase 2/3 data reported 84% cystectomy avoidance at three years and complete responses beyond 53 months. Grade 3 adverse events were reported in 4% of patients.